Search / Trial NCT06231498

The Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis

Launched by MEYER CHILDREN'S HOSPITAL IRCCS · Jan 29, 2024

Trial Information

Current as of December 21, 2024

Not yet recruiting

Keywords

Epigenome Dna Methylation Eosinophilic Granulomatosis With Polyangiitis Egpa

ClinConnect Summary

Background and Rationale. Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare multisystem immune-mediated disease classified both among Anti Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis and among hypereosinophilic disorders. Current scientific knowledge describes EGPA as a complex or multifactorial nature of the disease, i.e. the disease is triggered by a combination of inherited genetic variants and environmental factors. The term "epigenetics" refers to heritable alterations in gene expression which do not correspond to a variation in the underlying DNA sequence...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients over 18 years of age who meet the 1990 American College of Rheumatology classification criteria for EGPA or the criteria proposed in the MIRRA trial, or the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria;
  • Written informed consent from all the study participants.
  • Exclusion Criteria:
  • Patients with inadequate or unavailable data regarding response to treatment at months 6 and 12 after Mepolizumab initiation will be included in the case-control Epigenome-Wide Association Study (EWAS) but not in the predictive epigenomic study;
  • Patients with childhood-onset EGPA;
  • Patients who are pregnant or breast-feeding.

Trial Officials

Augusto Vaglio, MD, PhD

Principal Investigator

Meyer Children's Hospital IRCCS

About Meyer Children's Hospital Irccs

Meyer Children's Hospital IRCCS is a leading pediatric research institution based in Italy, dedicated to advancing child healthcare through innovative clinical trials and research initiatives. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it combines clinical excellence with rigorous scientific inquiry, focusing on various pediatric conditions. The hospital collaborates with multidisciplinary teams to enhance treatment protocols, improve patient outcomes, and contribute to the global body of knowledge in pediatric medicine. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the highest level of integrity and care.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0